21 results
8-K
EX-4.1
TPST
Tempest Therapeutics Inc
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
the singular and the plural forms of such term, and words denoting any gender include all genders; and (f) the words “include” and “including,” and variations
PRE 14A
79mxbsovfksypsu5 ik
22 Apr 22
Preliminary proxy
4:01pm
8-K
EX-10.4
uyi975 py9s9
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
EX-10.2
d8epmtaes
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
EX-10.3
tvsxhg8bc
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
EX-2.2
cx0 06b6tg2tb0f4
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
8-K
EX-2.1
4ye60 o89vd6yep
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
8-K
EX-2.3
jyy9i69r
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
425
EX-2.2
jnzgubp8nx8r
9 Aug 18
Business combination disclosure
5:17pm
425
EX-2.1
jgwhe f50zowq
9 Aug 18
Business combination disclosure
5:17pm
425
EX-2.3
xwf1uk
9 Aug 18
Business combination disclosure
5:17pm
10-12G/A
EX-10.23
97d44f07x
17 May 12
Registration of securities (amended)
12:00am
10-12G
EX-10.21
r9s2owik92nrpe
11 Apr 12
Registration of securities
12:00am